Imaging Technology News

Breast Cancer Study Reveals Challenges in Combining Focused Ultrasound with Immunotherapy

tim.hodson — Wed, 30 Sep 2026 16:44:47 +0000

tim.hodson Wed, 09/30/2026 - 11:44

Sept. 29, 2026 — A research team at the University of Virginia (UVA) led by Timothy Bullock, PhD, has published results from a Focused Ultrasound Foundation-funded preclinical study examining whether targeting immunosuppressive immune cells could enhance thermally ablative focused ultrasound for the treatment of triple-negative breast cancer (TNBC). The approaches did not improve focused ultrasound–mediated tumor control, but the results revealed several biological and safety challenges that could inform future combination strategies.

Why Triple-Negative Breast Cancer Is Difficult to Treat

TNBC is an aggressive form of breast cancer that lacks three target receptors that are commonly used to treat other types of breast tumors. Without these targets, treatment options are more limited. In addition, TNBC tumors often contain large numbers of immunosuppressive myeloid cells. These cells can restrain T cells, support tumor growth, and help create a tumor microenvironment that resists immune attack.

Investigating the Role of Immune Suppression

Thermally ablative focused ultrasound uses concentrated acoustic energy to heat and destroy targeted tumor tissue. In addition to reducing the tumor directly, thermal ablation can release tumor antigens and other signals that may alert the immune system. The UVA team previously found that combining thermal focused ultrasound with the chemotherapy gemcitabine improved tumor control in a mouse model of TNBC through a T cell dependent mechanism, although the response was not durable. Because gemcitabine can affect immunosuppressive myeloid cells that restrain T cell activity, the researchers questioned whether relieving this immune suppression contributed to the improved response.

In a subsequent Foundation-funded study, the team found that although gemcitabine reduced myeloid cells in circulation, it did not reduce these cells within the tumor as anticipated. This finding prompted the researchers to explore other ways of manipulating the myeloid cells within the tumor microenvironment.

To investigate this possibility, Dr. Bullock’s team tested whether removing immunosuppressive myeloid cells or attempting to reprogram them could strengthen the immune effects of focused ultrasound. They evaluated several approaches in two mouse models of TNBC; they used chemotherapies and antibodies to reduce certain myeloid cell populations and compounds called toll-like receptor agonists, intended to stimulate or reprogram immune cells. They then combined the most promising antibody- and immune-stimulating approaches with thermally ablative focused ultrasound.

What the Researchers Found

The tested strategies changed parts of the immune environment, but none produced the durable, selective myeloid-cell changes needed to improve focused ultrasound–mediated tumor control.

The findings refine the team’s earlier work: The benefit previously observed with gemcitabine and thermal focused ultrasound may not have resulted from relieving myeloid-cell suppression. Direct effects on tumor cells or other components of the tumor microenvironment may instead contribute to the response.

This research was funded by the UVA Cancer Center, the UVA Microbiology, Immunology, and Cancer Biology Department, and the Focused Ultrasound Foundation.

See Cells (Open Access)

Wednesday, September 30, 2026 - 11:44

New Research Network Helps Track Disease Patterns with Whole-Body MRI

tim.hodson — Wed, 30 Sep 2026 16:14:54 +0000

tim.hodson Wed, 09/30/2026 - 11:14

Sept. 29, 2026 — Prenuvo has launched the Prenuvo Research Network (The Network) to shift the healthcare paradigm from reactive to proactive. The Network is an initiative bringing together Prenuvo's AI tools, internal R&D teams, scientists and academic institutions to build the evidence base for proactive, preventive medicine.

The Network's research is powered by the Prenuvo Imaging Biobank — a proprietary collection of high quality whole-body MRI scans obtained with standardized, research-grade protocols and equipment. With more than 200,000 whole-body MRI scans completed, the Biobank enables researchers to help study disease patterns years before symptoms may appear.

Leveraging the Prenuvo Imaging Biobank, the Network is dedicated to studying early signs of structural and physiological changes in the human body, building an unprecedented picture of how disease develops over time. Early findings are beginning to generate meaningful insights into high-burden non-communicable diseases, including cardiovascular risk, cancer, metabolic conditions and neurodegenerative disorders.

The Network's initial collaborators represent experts from more than 50 institutions, including City of Hope, UCSF, and Moffitt Cancer Center. Unlike traditional academic research constrained by lengthy grant cycles and narrow focus areas, the Network is built to be collaborative and clinically driven, examining real-world medical questions and led by Prenuvo's in-house Medical Affairs and AI Research organization.

This initiative builds upon Prenuvo's growing research portfolio, including internal Hercules and Polaris studies, which examine the effectiveness of whole-body MRI screening for early disease detection. All research follows applicable ethical, patient safety, data integrity and regulatory compliance requirements including collaborator institution IRB review where required.

"The launch of the Prenuvo Research Network marks a groundbreaking moment for the future of healthcare. We're creating a research ecosystem that brings together cutting-edge AI, the largest internal database of whole-body MRI scans, and leading academic institutions—all united in the mission to transform proactive care," said Dr. Alex Exuzides, VP and Head of Research & Medical Affairs at Prenuvo. "The Prenuvo Research Network is designed to generate high-quality, real-world evidence on the role of whole-body MRI in clinical care. By combining a large-scale imaging dataset with rigorous analysis, we're able to study early patterns of disease in ways that have not been possible before. Our goal is to build a strong evidence base for proactive, preventive healthcare through collaborative, clinically grounded research."

"My laboratory's research focuses on bridging knowledge of peripheral diseases such as obesity to higher risk of neurological disorders, mainly Alzheimer's disease," said Dr. Cyrus Raji, MD, PhD, Associate Professor of Radiology at Washington University School of Medicine in St. Louis. "Access to high-quality research databases that image the body and brain is essential to building on the success of this work."

"We're seeing a troubling rise in lung cancer among people who don't fit the traditional risk profiles, especially never-smokers and women," said Dr. Lary Robinson, Thoracic Oncologist at Moffitt Cancer Center. "Working with Prenuvo, we're studying patients outside current screening guidelines to better understand which factors beyond smoking might signal elevated lung cancer risk. With access to de-identified data from Prenuvo's large internal dataset, we have a unique opportunity to explore early signs like lung nodules and connect them to the full picture of individual risk."

"City of Hope recently piloted the use of whole-body MRI alongside multi-cancer early detection blood testing in individuals with a strong family history of cancer. We found this approach may help detect cancers — sometimes in earlier stages — and may reduce patients' worries surrounding the disease. Further research will help clarify the role of whole-body MRI in early cancer detection," says Dr. Dan Raz, MD, Professor of Thoracic Surgery, Director of Lung Cancer Screening, and Co-Director of the Lung Cancer and Thoracic Oncology Program at City of Hope.

"Early detection can be a game changer for conditions where progressive growth and possibly even malignant transformation are the natural history," said Dr. Jacob Young, Assistant Professor, Department of Neurological Surgery, University of California, San Francisco. "Using Prenuvo's de-identified data sets to help define the frequency and characteristics of incidentally discovered lesions can improve our decision-making and management for patients now and in the future."

Initial Research Highlights
The Prenuvo Research Network launches with four featured studies, including peer-reviewed abstracts.

Significant Pulmonary and Mediastinal Findings in Patient Driven MRI Whole Body Screening

This study, representing the largest analysis of pulmonary and mediastinal findings on WB-MRI to date, establishes that clinically significant intrathoracic abnormalities — including findings concerning malignancy — can be detectable at meaningful rates in patients undergoing patient-driven preventive screening. These results highlight the potential of WB-MRI to extend cancer detection beyond guideline-eligible populations and underscore the need for prospective research into its impact on lung cancer mortality. Learn more.

Incidental Brain Findings in more than 78,000 Individuals from the General Population Undergoing Preventive Whole-Body MRI

This study provides the largest population-level characterization of incidental intracranial findings detected through preventive whole-body MRI, revealing that clinically significant brain abnormalities — including aneurysms, infarcts, and meningiomas — occur in 7% of screened individuals. These findings underscore the value of screening MRI in uncovering silent but actionable neurological pathology, and call for further investigation into the downstream clinical management and outcomes of incidentally detected brain findings at scale. Learn more.

Whole-Body and Brain Changes Associated with Alcohol Intake in Adults Without Alcohol Use Disorder

This study uniquely links alcohol consumption with structural changes in both brain and body organs among non-AUD individuals. These findings prompt further investigation into alcohol's broader health implications, particularly concerning cross-organ relationships and their clinical significance. Learn more.

Incidental Renal Findings Across 117,826 Whole-Body MRI Scans

This study uniquely characterizes the prevalence and risk profile of incidentally detected renal lesions across the largest whole-body MRI cohort to date, demonstrating that while the vast majority of findings are small and likely benign, clinically concerning lesions follow known RCC risk patterns. These findings prompt further investigation into the role of whole-body MRI in early renal cancer detection and the clinical frameworks needed to appropriately triage incidental findings at a population scale. Learn more.

Wednesday, September 30, 2026 - 11:14

Siemens Healthineers Receives ASTRO's Inaugural Corporate Partner Award

tim.hodson — Tue, 29 Sep 2026 16:49:11 +0000

tim.hodson Tue, 09/29/2026 - 11:49

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural recipient of its Corporate Partner Award, a new recognition honoring an organization whose extraordinary commitment, generosity and collaboration have made a lasting impact on the field of radiation oncology and patients worldwide.

The award was presented at the 2026 ASTRO Annual Meeting in Boston. Siemens Healthineers also was recognized tat the first ASTRO Gold Medal Gala, which honors leaders and partners across the radiation oncology community while raising funds to advance radiation medicine research through Speed of Light – The ASTRO Foundation.

“Collaboration across the radiation oncology community is essential to moving our field forward and improving care for patients,” said ASTRO CEO Vivek S. Kavadi, MD, MBA, FASTRO. “For decades, Siemens Healthineers and Varian have worked alongside radiation oncology professionals as the science and technology of cancer treatment have evolved. Their longstanding partnership with ASTRO reflects a shared commitment to continued innovation and to expanding what is possible for people with cancer.”

Long-Standing Corporate Member

Siemens Healthineers, through Varian, is one of ASTRO’s longest-standing corporate members. A pioneer in radiation oncology technology, the company has contributed to advances that shaped modern radiation therapy and continue to influence how treatment is planned and delivered today. Its partnership with ASTRO has also sustained research and workforce development across the career pipeline, including support for industry-based clinical research fellowships for resident physicians and ASTRO’s Medical Student Fellowship Awards, which provide medical students with mentored research experiences in radiation medicine.

“We are honored to receive ASTRO’s inaugural Corporate Partner Award,” said Arthur Kaindl, head of Varian, the Siemens Healthineers cancer-care business. “Our work with ASTRO keeps us closely connected to the challenges facing radiation oncology and to the people delivering care every day. That perspective is essential as we work to develop technologies that can make a meaningful difference for patients.”

ASTRO established the Corporate Partner Award in 2026 to recognize a corporate partner whose longstanding support of the radiation oncology community has advanced patient care and ASTRO’s mission. The new award reflects the important role that collaboration with industry can play in addressing the evolving needs of the field.

Tuesday, September 29, 2026 - 11:49

Imaging in Switzerland 2027

tim.hodson — Mon, 28 Sep 2026 17:09:49 +0000

tim.hodson Mon, 09/28/2026 - 12:09

Event Date

Sun, 06/06/2027 - 12:00 - Fri, 06/11/2027 - 12:00

Location

Zurich and Montreux, Switzerland

https://www.globalradiologycme.com/imaging-in-switzerland-2027

Penn Medicine, IBA Form Joint Venture to Advance Proton Therapy, Radiation Oncology

tim.hodson — Mon, 28 Sep 2026 16:47:17 +0000

tim.hodson Mon, 09/28/2026 - 11:47

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation and long-term operational performance.

The new company brings together the clinical, operational, research and education expertise of Penn Medicine with IBA's global leadership in proton therapy technology, project development, and implementation capabilities. The joint venture will provide integrated advisory and lifecycle support services that help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs.

As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems around the world are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.

Proton Therapy Expertise

"By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs," said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.

"A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption" added Henri de Romrée, Deputy CEO of IBA.

Unlike traditional advisory models, the joint venture combines the perspectives of a world-leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.

Visit Noventra’s website to learn more about Noventra’s services.

Monday, September 28, 2026 - 11:47

Leica Biosystems Adds Pathology Products to AI Store

tim.hodson — Fri, 25 Sep 2026 18:43:59 +0000

tim.hodson Fri, 09/25/2026 - 13:43

Sept. 24, 2026 — Leica Biosystems,has added two Paige digital pathology AI-enabled products from Tempus to its Aperio AI Store — a unified, interoperable digital pathology platform that provides multiple AI-powered applications in a single interface. Designed to simplify adoption and accelerate the use of advanced image analysis, the Aperio AI Store helps turn complex pathology images into actionable research insights that could ultimately drive the future of patient care.

By bringing partner applications into a streamlined workflow, the Aperio AI Store helps laboratories and researchers generate insights from pathology images more efficiently and at scale, supporting broader adoption of computational pathology and helping unlock the full value of digital pathology data for cancer research.

The newly available products include Paige PanCancer Detect, a research application designed to identify suspicious areas across more than 40 cancer types, powered by Tempus’ pathology foundation model. The release also features Paige Prostate, a suite of AI-powered research applications — including Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Perineural Invasion — that support the assessment of prostate cancer features in H&E-stained whole slide images. Both products are for research use only and are not intended for diagnostic or clinical use.

Aperio AI Store

The Aperio AI Store is designed to simplify and scale AI adoption by bringing partner algorithms directly into the Aperio HALO AP^* software workflow. Instead of navigating separate software interfaces for each algorithm or vendor, users can access a broad and growing selection of curated AI applications through one consistent experience. For laboratories evaluating multiple AI tools across diverse case types, this approach can help reduce complexity and support more efficient adoption.

“Nearly one year after launch, the Aperio AI Store is helping move AI in digital pathology from individual applications toward a more connected and scalable experience,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “Tempus brings highly differentiated AI capabilities to our ecosystem, giving laboratories more choice while allowing them to access these technologies within a workflow they already know. This is an important step toward making AI more practical, scalable, and ultimately more impactful in pathology.”

Available exclusively through the Aperio HALO AP image management system, the Aperio AI Store has gained momentum since its U.S. launch in October 2025 by offering a practical suite of AI tools within a pathologist-centric, interoperable digital pathology workspace.

“Our collaboration with Leica Biosystems allows us to bring our AI-enabled computational pathology products directly into the daily workflows of more researchers worldwide,” said Razik Yousfi, senior vice president and general manager of AI products at Tempus. “By embedding the Paige offerings into the Aperio HALO AP software ecosystem, we are making advanced image analysis more accessible, seamless, and actionable for oncology research.”

The new applications will be showcased alongside Leica Biosystems' broader portfolio of digital pathology and workflow innovations at the Digital Pathology Association's Pathology Visions 2026, taking place October 16-18 in San Diego, California. Attendees can visit booth 401 to experience live demonstrations, engage with Leica Biosystems experts, and explore how the company's flexible, end-to-end solutions help laboratories of all sizes deliver high-quality pathology insights that drive research breakthroughs and better patient outcomes.

Aperio HALO AP is developed in partnership with Indica Labs.

*In the USA Aperio HALO AP is For Research Use Only. Not for Use in Diagnostic Procedures. Aperio HALO AP is CE-IVDR marked in the EU. All other products are For Research Use Only. Not for Use in Diagnostic Procedures.

Friday, September 25, 2026 - 13:43

Accuray, RaySearch to Collaborate on Online Adaptive Radiation Therapy

tim.hodson — Fri, 25 Sep 2026 16:23:28 +0000

tim.hodson Fri, 09/25/2026 - 11:23

Sept. 11, 2026 — Accuray Inc. and RaySearch Laboratories have announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.

The collaboration combines Accuray's advanced photon-based radiation therapy platforms and imaging capabilities with RaySearch's treatment planning and workflow software to enable online adaptive radiation therapy. The initial focus is on Accuray's Radixact and the solution will be extended to the CyberKnife platform in the future.

Online adaptive radiation therapy allows treatment plans to be adjusted immediately before treatment based on the patient's anatomy at the time of delivery. By bringing imaging, treatment planning and care coordination together, the solution is designed to support more personalized treatments while helping clinics work more efficiently.

Online Adaptive Radiation Therapy

Under the agreement, Accuray has agreed to purchase specified RayStation licenses to support the commercialization of online adaptive radiation therapy solutions, which the parties will then jointly market and support. The collaboration will also leverage RayCare technology to simplify connectivity between clinical systems and support efficient online adaptive workflows. In connection with the collaboration, RaySearch will further enhance its software to support the Radixact platform, enabling a more integrated workflow for online adaptive radiation therapy.

"Advanced software is a key enabler of online adaptive radiation therapy. By combining RayStation and RayCare technology with Accuray's imaging and treatment delivery technologies, we are creating a comprehensive solution designed to simplify implementation and help more clinics adopt adaptive radiation therapy," says Johan Löf, founder and CEO of RaySearch. "Accuray's global presence, large installed base, differentiated technology, and worldwide service capabilities made them an ideal partner for us."

"Strategic partnerships are an important part of Accuray's growth strategy, enabling us to accelerate innovation while focusing on our core strengths. RaySearch's expertise in treatment planning, workflow software and system integration makes them a valuable partner as we advance our online adaptive radiation therapy strategy. By combining our complementary capabilities, we aim to bring efficient and personalized adaptive treatments to more patients worldwide," commented Steve LaNeve, CEO of Accuray.

Friday, September 25, 2026 - 11:23

Penn Medicine Experts to Make Presentations at ASTRO

tim.hodson — Thu, 24 Sep 2026 16:51:17 +0000

tim.hodson Thu, 09/24/2026 - 11:51

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn’s Perelman School of Medicine will give several presentations at the American Society for Radiation Oncology's (ASTRO) 68th annual meeting, Sept. 26-30, in Boston.

At the meeting, Neha Vapiwala, MD, FACR, FASTRO, FASCO, the Eli J. Glatstein Professor in Radiation Oncology, will address attendees as president of ASTRO. She is the first Penn faculty member to lead the premier society for radiation oncology professionals and recently shared her insights for advancing a medical career at any stage — from applying to medical school to professional development.

Key Presentations

Dozens of Penn trainees and faculty members will participate in the meeting by presenting their research and moderating scientific, educational and workshop sessions. Additionally, James Metz, MD, chair of Radiation Oncology, will moderate the second Keynote Address with former FDA Commissioner Scott Gottlieb, MD, on Sept. 29. Penn presentation highlights include:

On Sept. 28, Ezekiel Emanuel, MD, PhD, Vice Provost for Global Initiatives at the University of Pennsylvania, will deliver the first keynote session, sharing his perspective in relation to the 2026 meeting theme: "Data to Dialogue: Communicating Radiotherapy's Value to Advance Care."

Also on Sept. 28, Neha Vapiwala, MD, FACR, FASTRO, FASCO, the Eli J. Glatstein Professor in Radiation Oncology, will share priorities and insights from ASTRO leadership to advance the value and perceptions of radiotherapy’s role in clinical care, and to address challenges and opportunities for strengthening professional development and patient outcomes.

Michelle Alonso-Basanta, MD, PhD, professor of Radiation Oncology and chief of the Central Nervous System Service, is presenting on “Advances in Multimodal Therapy for Glioblastoma: From Phase I to Phase III Trials” on Sept. 29. She is also co-moderator of the session and was recently named to the 2026 Class of ASTRO Fellows.

Visit the Penn Radiation Medicine Institute (PRMI) at Booth #1722 and the University of Pennsylvania Radiation Oncology Education Programs at Booth #1759.

Thursday, September 24, 2026 - 11:51

SW Mississippi Regional Medical Center Installs Philips Rembra CT System

tim.hodson — Thu, 24 Sep 2026 15:24:28 +0000

tim.hodson Thu, 09/24/2026 - 10:24

Sept. 17, 2026 — Royal Philips and Southwest Mississippi Regional Medical Center (SMRMC), which serves as the hub of Southwest Health, recently announced that the hospital has installed the first Philips Rembra CT system for acute and high-demand imaging environments in the United States. The system is designed to support the McComb hospital’s high-demand emergency imaging environment with the goal of expanding local access to advanced diagnostic services for patients throughout southwest Mississippi.

SMRMC serves small towns and rural communities across the region and is now using Rembra CT in its emergency and general radiology departments. Designed to accelerate scanning and image reconstruction, Rembra may reduce the time patients spend on the table and help clinicians manage high patient volumes in emergency settings, where every minute matters.

“As healthcare continues to evolve, our goal is to invest in technology that not only advances clinical care but also improves the patient experience,” said Brent Albritton, Director of Radiology at SMRMC. “Our team is already seeing practical day-to-day benefits, including faster system initialization, more efficient image selection, helpful 3D tools and easier patient positioning. These improvements are helping us meet demand while continuing to expand diagnostic services for our community here in McComb.”

Philips Rembra CT

Designed for acute and high-demand imaging environments, the FDA 510(k)-cleared Philips Rembra CT combines advanced detector technology, AI-enabled workflows and rapid image reconstruction designed to make images available in near-real time and support timely clinical decision-making in settings such as emergency and trauma care¹. The Rembra CT can support up to 270 patient exams per day in throughput testing, helping imaging departments manage growing patient volumes².

With the largest-in-class 85 cm bore, the system is designed to help facilitate patient access and positioning [1]. SMRMC also sees an opportunity to further develop its imaging services, including cardiac CT angiography and virtual colonoscopy, as its clinical programs and staffing continue to grow.

“Emergency departments are under constant pressure to move quickly while managing significant patient volumes and clinical complexity,” said Brian Murphy, Vice President, Head of Imaging, North America, Philips. “For community hospitals like SMRMC, access to advanced imaging technology designed for speed, consistency and workflow efficiency can help care teams get the information they need sooner and make more confident decisions when time matters most. With Philips’ Rembra CT, the hospital is strengthening emergency care and helping more patients access advanced imaging close to home.”

References

Based on publicly available manufacturer specifications for leading radiology CT systems as of March 2026 on reconstruction speed in this class of scanners and bore size.
Based on a 16-hour day and throughput testing of 203 patient scans over 12 hours using typical radiology profiles and protocols.

Additional information on Philips

Thursday, September 24, 2026 - 10:24

AI Certificate Program Being Offered by RSNA

tim.hodson — Thu, 24 Sep 2026 13:00:00 +0000

tim.hodson Thu, 09/24/2026 - 08:00

Sept. 22, 2026 — The Radiological Society of North America (RSNA) is now offering a certificate program that equips radiologists with on-demand, radiology-focused training to evaluate, implement and use imaging AI confidently and responsibly in real-world practice.

The program delivers practical, hands‑on education to help radiologists confidently evaluate and implement imaging AI in real‑world practice. Built by radiologists for radiologists, the program emphasizes clinically relevant skills you can apply immediately.

The program is an on-demand, self-paced course intended to support radiologists in using artificial intelligence in radiology. It consists of six modules of case-based and hands-on curriculum featuring expert instructors.

Click here to learn more about the program and to enroll.

Thursday, September 24, 2026 - 08:00